Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flomoxef. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | CMA1 | P23946 | 18/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flomoxef SCHEMBL14423926 | 1.00 | PTGS1 (0.57) | PTGS1CMA1HSD17B10TDP1 | |
| Flomoxef SCHEMBL65125 | 0.99 | PTGS1 (0.57) | PTGS1CMA1HSD17B10TDP1 | |
| Flomoxef SCHEMBL27661462 | 0.99 | PTGS1 (0.57) | PTGS1CMA1HSD17B10TDP1 | |
| Flomoxef SCHEMBL30531854 | 0.93 | HSD17B10 (0.58) | PTGS1CMA1HSD17B10TDP1 | |
| Flomoxef SCHEMBL30716855 | 0.93 | HSD17B10 (0.58) | PTGS1CMA1HSD17B10TDP1 | |
| Flomoxef SCHEMBL27896310 | 0.92 | PTGS1 (0.51) | PTGS1CMA1HSD17B10TDP1 | |
| SCHEMBL30515648 | 0.86 | CMA1 (0.60) | PTGS1CMA1 | |
| Flomoxef SCHEMBL30515667 | 0.82 | PTGS1 (0.44) | PTGS1CMA1HSD17B10TDP1 | |
| Flomoxef SCHEMBL18065040 | 0.78 | NR1I2 (0.58) | PTGS1HSD17B10TDP1 | |
| Flomoxef SCHEMBL2563269 | 0.78 | ABCB11 (0.53) | PTGS1CMA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6602 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| US-20250222118-A1 | Beta-Lactam-Cannabinoid Conjugate Molecules | DIVERSE BIOTECH INC (US) | 2025-07-10 | — | — | US | claimed |
| US-5874455-A | THIOL OR DISULFIDE DERIVATIVES FOR CATARACTS | GAKKO HOJIN KINKI DAIGAKU (JP) | 1999-02-23 | — | — | US | claimed |
| US-5763603-A | HIGH BETA-LACTAMASE INHIBITORY ACTIVITY IN COMBINATION WITH BETA-LACTAM ANTIBIOTICS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| EP-0678095-A1 | CRYSTALLINE PENICILLIN DERIVATIVE, AND ITS PRODUCTION AND USE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1995-10-25 | — | — | EP | claimed |
| EP-0384410-B1 | Antimicrobial composition | BANYU PHARMA CO LTD (JP) | 1995-05-17 | — | — | EP | claimed |
| WO-1995012601-A1 | CRYSTALLINE PENICILLIN DERIVATIVE, AND ITS PRODUCTION AND USE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-11 | — | — | WO | claimed |
| CN-1093089-A | Cephalosporin salts and process for their preparation | HOECHST AG (DE) | 1994-10-05 | — | — | CN | claimed |
| EP-0603755-A2 | Cephalosporin salts and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-29 | — | — | EP | claimed |
| EP-0384410-A1 | Antimicrobial composition | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-08-29 | — | — | EP | claimed |